New England Biolabs

New England Biolabs® launches Monarch® Mag Viral DNA/RNA Extraction Kit to enable highly sensitive viral detection

Retrieved on: 
Thursday, April 11, 2024
Saliva, RNA, Research, Monarch, New England Biolabs, Automation, DNA, NEB, Virus, Plastic, Infection, Vaccine

IPSWICH, Mass., April 11, 2024 /PRNewswire/ -- New England Biolabs (NEB®) announces the release of its Monarch Mag Viral DNA/RNA Extraction Kit. This extraction kit enhances recovery of low amounts of viral nucleic acid to enable highly sensitive detection. The kit uses a magnetic bead-based process to extract viral RNA and DNA reproducibly and efficiently, while enabling scale up for high-throughput automation. The kit is compatible with the most common sample types for extracting viral nucleic acids, including saliva, respiratory swab samples and, following an enrichment step, wastewater samples.

Key Points: 
  • IPSWICH, Mass., April 11, 2024 /PRNewswire/ -- New England Biolabs (NEB®) announces the release of its Monarch Mag Viral DNA/RNA Extraction Kit.
  • This extraction kit enhances recovery of low amounts of viral nucleic acid to enable highly sensitive detection.
  • The kit uses a magnetic bead-based process to extract viral RNA and DNA reproducibly and efficiently, while enabling scale up for high-throughput automation.
  • The Monarch Mag Viral DNA/RNA Extraction Kit complements NEB's downstream amplification and library prep for next-generation sequencing applications, and can be utilized with these product lines accordingly.

New England Biolabs® opens subsidiary in the Republic of Korea

Retrieved on: 
Wednesday, April 3, 2024
Growth, Partnership, NEB, Research, New England Biolabs, Public sector, International business, South Korea

IPSWICH, Mass., April 3, 2024 /PRNewswire/ -- New England Biolabs (NEB®), a world leader in the production of reagents for the life science industry, extended its global subsidiary network with the opening of New England Biolabs Korea Ltd. (NEB Korea).

Key Points: 
  • IPSWICH, Mass., April 3, 2024 /PRNewswire/ -- New England Biolabs (NEB®), a world leader in the production of reagents for the life science industry, extended its global subsidiary network with the opening of New England Biolabs Korea Ltd. (NEB Korea).
  • The Republic of Korea is emerging as a global leader in the life science space, as a result of strong public sector support and private sector investments.
  • NEB Korea will now bring a higher level of service to our valued customers and local distributors in this important market.
  • NEB also maintains subsidiary offices in Australia, Canada, China, France, Germany, Japan, New Zealand, Singapore and the United Kingdom.

New England Biolabs® Commemorates 50th Anniversary with Series of Events to Celebrate Customers

Retrieved on: 
Monday, April 1, 2024
Natural Resources, NEB, Travel, Environmental stewardship, New England Biolabs, Creativity, Marketing, World Tour, The arts, Pharmaceutical industry

IPSWICH, Mass., April 1, 2024 /PRNewswire/ -- In commemoration of its 50th anniversary, New England Biolabs (NEB®) today announced an invitation for scientists to submit applications for its 2024 Passion in Science Awards, which recognize members of the scientific community who are committed to making a difference through their science, humanitarian service, environmental stewardship, and/or artistic and creative spirit. Awardees will be celebrated on October 9th and 10th at the NEB campus in Ipswich, MA, USA.

Key Points: 
  • "In 2014, NEB introduced the Passion in Science Awards to recognize those within the scientific community working to solve many of today's challenges.
  • "We are thrilled to be hosting the Passion in Science Awards again this year as part of our 50th anniversary celebration."
  • "It is fitting to host the Passion in Science Awards as part of our 50th anniversary celebration."
  • NEB will be hosting other 50th anniversary events throughout the year, including its 50-stop World Tour, Donald G. Comb Memorial Lecture, and various special offers.

New England Biolabs® Launches NEBNext® Enzymatic 5hmC-seq Kit, for enzyme-based 5hmC detection at single-base resolution

Retrieved on: 
Tuesday, February 13, 2024
Methylation, Research, DNA repair, Tissue, Gold, New England Biolabs, DNA, Cytosine, Fine chemical

IPSWICH, Mass., Feb. 13, 2024 /PRNewswire/ -- New England Biolabs (NEB®) today announced the launch of the NEBNext Enzymatic 5hmC-seq Kit (E5hmC-seq™), a novel enzyme-based method for the specific detection of 5hmC sites. The gentle, enzyme-based approach enables high yields and high-quality data, with an input range of 100 pg to 200 ng.

Key Points: 
  • IPSWICH, Mass., Feb. 13, 2024 /PRNewswire/ -- New England Biolabs (NEB®) today announced the launch of the NEBNext Enzymatic 5hmC-seq Kit (E5hmC-seq™), a novel enzyme-based method for the specific detection of 5hmC sites.
  • "While NEBNext Enzymatic Methyl-seq (EM-seq™), our gold standard for methylation detection, detects both 5mC and 5hmC, it does not distinguish between them.
  • "To address these challenges, we developed the NEBNext Enzymatic 5hmC-seq Kit, which allows for the specific detection of 5hmC sites using a two-step enzymatic conversion workflow," said Stewart.
  • "The enzymatic method minimizes DNA damage and allows for the discrimination of 5hmC from unmodified cytosine and 5mC after Illumina® sequencing.

GMGI Appoints Dr. Andrew Gardner as Inaugural Chief Scientific Officer

Retrieved on: 
Wednesday, February 7, 2024
Growth, Life, Science, Research, DNA, Economic development, Environment, Protein, CSO, Modification, Genomics, Proteomics, Education, Vent pecking, Health, Innovation, New England Biolabs, Workforce, Fine chemical

GLOUCESTER, Mass., Feb. 7, 2024 /PRNewswire/ -- Gloucester Marine Genomics Institute (GMGI), a 501c3 non-profit addressing critical challenges facing our oceans, human health, and the environment through innovative scientific research and education, announced the appointment of Dr. Andrew Gardner as the organization's inaugural Chief Scientific Officer (CSO).

Key Points: 
  • GLOUCESTER, Mass., Feb. 7, 2024 /PRNewswire/ -- Gloucester Marine Genomics Institute (GMGI), a 501c3 non-profit addressing critical challenges facing our oceans, human health, and the environment through innovative scientific research and education, announced the appointment of Dr. Andrew Gardner as the organization's inaugural Chief Scientific Officer (CSO).
  • Dr. Gardner brings an impressive track record of discovery, innovation and team leadership after 28 years at New England Biolabs, in Ipswich, MA, most recently as Scientific Director of Molecular Enzymology.
  • As CSO, Dr. Gardner will drive the scientific strategy for GMGI's next phase of growth.
  • "We are delighted to have Dr. Gardner join the GMGI team in this capacity.

Ribbon Biolabs Appoints Jodi Barrientos Chief Executive Officer; Founder Harold De Vladar Named an Advisor and Board Member

Retrieved on: 
Wednesday, December 6, 2023
Biotechnology, Health, Science, Pharmaceutical, Research, Barrientos, DNA, Pathology, Commercial, Commercial Operating System, Roche, Genomics, Agilent Technologies, New England Biolabs, Advertising, Molecular biology, Growth, Microbiology, Purdue University, Qiagen, Management

Ribbon Biolabs GmbH, the DNA synthesis company, announced today that its Board of Directors had appointed Jodi Barrientos as interim Chief Executive Officer.

Key Points: 
  • Ribbon Biolabs GmbH, the DNA synthesis company, announced today that its Board of Directors had appointed Jodi Barrientos as interim Chief Executive Officer.
  • Ms. Barrientos, who joined the company this year as Chief Business Officer, brings substantial market experience to Ribbon Biolabs, as it moves forward with its commercialization plan.
  • Founder and former CEO Harold de Vladar, Ph.D., will serve as a senior advisor to the company and member of the Board.
  • Said Roopom Banerjee, Managing Partner of Whiteleaf Advisors, and Executive Chairman of the Board at Ribbon Biolabs, “We are so excited that Ribbon Biolabs has reached an inflection point under Harold’s leadership where commercial leadership is critical to the continued growth of the company.

Larta Institute Opens Call for Applications to Heal.LA Bioscience and Healthcare Accelerator

Retrieved on: 
Wednesday, November 8, 2023
Other Health, General Health, Professional Services, Entrepreneur, Philanthropy, Consumer, Start-Up, Small Business, Science, Biotechnology, Other Philanthropy, Health, Other Science, Knowledge, Rancho Los Amigos National Rehabilitation Center, Health care, Therapy, Food, Healing environments, Mental health, USC, Heal, California State University, Organization, Holism, Entrepreneurship, Gilead Sciences, Small business, Consortium, Medicine, Cedars-Sinai Medical Center, Keck Graduate Institute, Rio Hondo College, Innovation Hub, Keck School of Medicine of USC, SBA, California Office of Environmental Health Hazard Assessment, WuXi Biologics, Hospital, Management, New England Biolabs, Pediatrics

Larta Institute, a non-profit organization accelerating innovation and entrepreneurship to feed, fuel and heal the world, has opened a call for applicants to join the 2024 cohort of its Heal.LA Bioscience and Healthcare Accelerator.

Key Points: 
  • Larta Institute, a non-profit organization accelerating innovation and entrepreneurship to feed, fuel and heal the world, has opened a call for applicants to join the 2024 cohort of its Heal.LA Bioscience and Healthcare Accelerator.
  • The Heal.LA accelerator welcomes applications from innovators with ideas that have the potential to improve the health and wellness of underserved, urban communities.
  • Larta has designed our Heal.LA Bioscience and Healthcare Accelerator to help diverse founders advance innovations geared to the needs of underserved communities and to pilot the use of their solutions in these communities.
  • To learn more or apply to the Heal.LA Bioscience and Healthcare Accelerator, please visit: https://larta.org/programs/heal-accelerator/

New England Biolabs® Launches New NEBNext UltraExpress™ DNA and RNA Kits for Faster, Easier NGS Library Prep Workflows

Retrieved on: 
Friday, November 3, 2023
RNA, Associate Director of National Intelligence and Chief Information Officer, PCR, Fungus, University of Massachusetts Amherst, Messenger, Workflow, University, NEB, Library, Plastic, New England Biolabs, DNA, Automation, Vaccine, Illumina

IPSWICH, Mass., Nov. 3, 2023 /PRNewswire/ -- New England Biolabs (NEB®) today announced the release of the NEBNext UltraExpress DNA and RNA Library Prep Kits for next generation sequencing on the Illumina platform. These new kits are designed to generate high-quality, high-yield libraries with a faster, easier workflow, enabling RNA library prep in a single day, and DNA library prep in under two hours. The kits are suitable for a wide range of inputs (25 -250 ng total RNA and 10 – 200 ng mechanically sheared DNA) and utilize a single protocol that uses the same adaptor concentration and PCR cycle number for all input amounts. The workflows are automation friendly and minimize consumables waste.

Key Points: 
  • IPSWICH, Mass., Nov. 3, 2023 /PRNewswire/ -- New England Biolabs (NEB®) today announced the release of the NEBNext UltraExpress DNA and RNA Library Prep Kits for next generation sequencing on the Illumina platform.
  • These new kits are designed to generate high-quality, high-yield libraries with a faster, easier workflow, enabling RNA library prep in a single day, and DNA library prep in under two hours.
  • "We designed the NEBNext UltraExpress workflows to meet the need for substantially faster and easier library prep of samples within a standard input range.
  • Compared to the NEBNext® Ultra™ II Directional RNA kit, NEBNext UltraExpress RNA uses 21% fewer tubes and 25% fewer tips.

Complete Genomics demonstrates technical and commercial momentum in the sequencing market through new customers, partnerships and collaborations less than one year after launching in the U.S.

Retrieved on: 
Tuesday, October 31, 2023
Complete Genomics, ASHG, RNA-Seq, Nebula Genomics, Karkus, G400, Whole genome sequencing, IDT, Medical laboratory, Bio-Rad Laboratories, RNA, University of Massachusetts, Face, Professor, Research, SNP, Society, American Society of Human Genetics, Ecosystem, Partnership, WGS, Human genetics, Google AI, Sequoia, Integrated DNA Technologies, Automation, New England Biolabs, Integration, New England, Completeness, Stanford University School of Medicine, Antibiotics, Medical device, Genomics

At ASHG, Complete Genomics will highlight experts from Stanford Medicine, UMass Chan Medical School and Praxis Genomics to discuss how affordable and accurate genomic sequencing is changing the face of research.

Key Points: 
  • At ASHG, Complete Genomics will highlight experts from Stanford Medicine, UMass Chan Medical School and Praxis Genomics to discuss how affordable and accurate genomic sequencing is changing the face of research.
  • See the full description of speakers Complete Genomics is bringing to ASHG at completegenomics.com/ashg-2023-event-page .
  • Based in San Jose, CA, Complete Genomics celebrated its U.S. commercial launch of its DNBSEQ™ sequencing product line one year ago at ASHG 2022.
  • "Our collaboration with Complete Genomics underscores our commitment to providing researchers with advanced solutions for sequencing applications."

Ribbon Biolabs Appoints Roopom Banerjee as Executive Chairman

Retrieved on: 
Thursday, June 29, 2023
Biotechnology, Health, Science, Pharmaceutical, Research, DNA, Harvard Kennedy School, US, EU, Therapy, Public policy, MPP, Bain Capital, Harvard University, NGS, Senior advisor, Engineer Research and Development Center, Biomedical Research, Wall Street, CRG, MIT, Jonathan Rothberg, McKinsey & Company, New England Biolabs, Economics, Goldman Sachs, Kennedy School, Ribbon, Nested polymerase chain reaction, Initial public offering, Synthetic biology, PCR, Massachusetts Institute of Technology, Management, Fine chemical, Biology

Ribbon Biolabs, the DNA synthesis company, today announced the appointment of Roopom Banerjee as Executive Chairman of its Board of Directors.

Key Points: 
  • Ribbon Biolabs, the DNA synthesis company, today announced the appointment of Roopom Banerjee as Executive Chairman of its Board of Directors.
  • He brings 25 years of strategy, operations, business development, financial advisory, and investment experience in early and late-stage life science companies to Ribbon Biolabs.
  • "We are delighted to welcome Roopom Banerjee to Ribbon Biolabs as our inaugural Executive Chairman.
  • Ribbon Biolabs is a synthetic biology leader driving DNA synthesis beyond the limits of current technologies.